Open AccessEarly Insights From Clinical Trials of Typhoid Conjugate Vaccine
Author(s) -
Kathleen M. Neuzil,
Buddha Basnyat,
John D. Clemens,
Melita A. Gordon,
Priyanka Patel,
Andrew J. Pollard,
Mila Shakya,
Firdausi Qadri
Publication year - 2020
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/ciaa370
Subject(s) - typhoid fever , immunogenicity , tolerability , typhoid vaccine , clinical trial , medicine , conjugate , conjugate vaccine , immunology , virology , adverse effect , antigen , mathematics , mathematical analysis
Clinical trials of typhoid conjugate vaccine (TCV) are ongoing in 4 countries. Early data confirm safety, tolerability, and immunogenicity of typhoid conjugate vaccine, and early efficacy results are promising. These data support World Health Organization recommendations and planned country introductions. Forthcoming trial data will continue to inform programmatic use of typhoid conjugate vaccine.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom